Repligen (NASDAQ:RGEN) Upgraded at Wall Street Zen

Repligen (NASDAQ:RGEN) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

Several other brokerages have also recently weighed in on RGEN. Canaccord Genuity Group raised their price target on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research report on Wednesday, October 29th. Weiss Ratings lowered Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, January 30th. Barclays lifted their target price on Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. UBS Group increased their price target on Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Finally, Wells Fargo & Company lifted their price objective on shares of Repligen from $175.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $179.62.

Repligen Stock Performance

RGEN opened at $142.18 on Friday. Repligen has a 1-year low of $102.96 and a 1-year high of $175.77. The company has a market cap of $8.00 billion, a price-to-earnings ratio of 7,112.56, a PEG ratio of 2.53 and a beta of 1.13. The company’s fifty day moving average price is $161.90 and its two-hundred day moving average price is $144.83. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26.

Insider Buying and Selling at Repligen

In related news, Director Karen A. Dawes sold 275 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the transaction, the director directly owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. The trade was a 0.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO James Bylund sold 2,191 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total transaction of $331,301.11. Following the transaction, the chief operating officer owned 21,520 shares of the company’s stock, valued at approximately $3,254,039.20. The trade was a 9.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 49,657 shares of company stock worth $7,721,077 in the last quarter. 1.20% of the stock is currently owned by company insiders.

Institutional Trading of Repligen

Several hedge funds have recently added to or reduced their stakes in RGEN. Rhenman & Partners Asset Management AB grew its position in shares of Repligen by 333.3% in the second quarter. Rhenman & Partners Asset Management AB now owns 19,500 shares of the biotechnology company’s stock valued at $2,425,000 after purchasing an additional 15,000 shares in the last quarter. XTX Topco Ltd boosted its stake in Repligen by 34.1% in the 2nd quarter. XTX Topco Ltd now owns 17,352 shares of the biotechnology company’s stock worth $2,158,000 after purchasing an additional 4,417 shares during the period. Delta Investment Management LLC bought a new position in Repligen in the 3rd quarter worth about $6,779,000. Congress Asset Management Co. grew its holdings in Repligen by 43.4% during the 3rd quarter. Congress Asset Management Co. now owns 218,592 shares of the biotechnology company’s stock valued at $29,219,000 after buying an additional 66,142 shares in the last quarter. Finally, Blue Whale Capital LLP bought a new stake in shares of Repligen during the second quarter valued at about $35,782,000. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.